Welcome to our dedicated page for Genprex news (Ticker: $GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genprex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genprex's position in the market.
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, is supported by FDA Orphan Drug and Fast Track designations. Genprex highlighted the poor prognosis of ES-SCLC and the benefits of current treatments, emphasizing the potential of their therapy. Positive outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer have enabled an accelerated timeline for Acclaim-3.
Genprex, a clinical-stage gene therapy company, announced the appointment of Jose A. Moreno Toscano as Chairman of the Board following the passing of the previous Chairman, Rodney Varner. Mr. Moreno Toscano brings over 20 years of experience in the pharmaceutical and biotechnology industries, focusing on revenue growth, market expansion, and organizational development.
Genprex, a clinical-stage gene therapy company, announced the passing of its co-founder and CEO, Rodney Varner, due to complications from cancer. Ryan Confer has been appointed as the new President and CEO. Under Varner's leadership, the company achieved significant milestones in developing therapies for cancer and diabetes. The company expresses its condolences to Varner's family and colleagues.
Genprex, Inc. (